Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2026 | Buy | Canaccord Genuity | |
| 12/11/2024 | Buy | TD Cowen | |
| 2/9/2024 | Hold → Buy | Canaccord Genuity | |
| 9/21/2022 | Sell → Hold | Canaccord Genuity | |
| 6/24/2022 | Neutral → Overweight | Cantor Fitzgerald | |
| 6/6/2022 | Sell → Hold | Stifel | |
| 11/10/2021 | $9.60 → $10.75 | Neutral | Cantor Fitzgerald |
| 10/28/2021 | $9.50 → $9.60 | Neutral | Cantor Fitzgerald |
NASDAQ | TSX: ACBThe Company makes history as the first and only cannabis company to ever receive this recognitionEDMONTON, AB, July 9, 2026 /CNW/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) ("Aurora" or the "Company"), the Canadian-based leading global medical cannabis company, has been awarded on TIME Canada's Best Companies 2026 list. This win reflects the Company's differentiated performance and commitment to industry excellence. To view the full award list, visit TIME.com. This prestigious award is presented by TIME in collaboration with Statista, the world-leading statistics portal and industry ranking provider. Canada'
Shareholders are encouraged to keep an eye out for their meeting materials and vote early – every vote matters, no matter how many shares you own.Shareholders who have questions or need assistance with voting their shares voting should contact Aurora's strategic advisor and proxy solicitation agent, Kingsdale Advisors by telephone at 1-800-749-9052 or by email at contactus@kingsdaleadvisors.com or visit www.MyAuroraVote.comEDMONTON, AB, July 8, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX:ACB) (NASDAQ:ACB), a leading Canada-based global medical cannabis company, is pleased to announce that the management information circular (the "Circular") for the upcoming annual gen
NASDAQ | TSX: ACBAchieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growthDelivers Record Annual Adjusted EBITDA1 of $53.8 million, representing 32% YoY growthCompletes Accretive Acquisition of Safari Flower Company in April, an established EU-GMP Manufacturer, adding Critical Capacity to Serve Growing Profitable International MarketsMaintains Strong Balance Sheet with ~$164.7 million of Cash, Short Term Investments and Cash Equivalents2 with no DebtEDMONTON, AB, June 11, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial an
6-K - AURORA CANNABIS INC (0001683541) (Filer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
6-K - AURORA CANNABIS INC (0001683541) (Filer)
Canaccord Genuity initiated coverage of Aurora Cannabis with a rating of Buy
TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy
Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy
NASDAQ | TSX: ACB EDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries. "I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicated
The collaboration will improve medical cannabis access and better serve patients across Australia NASDAQ | TSX: ACB EDMONTON, AB, Dec. 2, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia. This strategic partnership will expand patient access to trusted, safe, and effective medical cannabis across Australia, while supporting healthcare professionals with educational resources. Leafio will serve as a wholesaler of Aurora's leading portfoli
VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary. "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impac
NASDAQ | TSX: ACBAchieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growthDelivers Record Annual Adjusted EBITDA1 of $53.8 million, representing 32% YoY growthCompletes Accretive Acquisition of Safari Flower Company in April, an established EU-GMP Manufacturer, adding Critical Capacity to Serve Growing Profitable International MarketsMaintains Strong Balance Sheet with ~$164.7 million of Cash, Short Term Investments and Cash Equivalents2 with no DebtEDMONTON, AB, June 11, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial an
NASDAQ | TSX: ACBEDMONTON, AB, May 28, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2026 on Thursday, June 11, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter and fiscal year 2026 before the opening of markets that same day. Conference Call DetailsDATE:Thursday, June 11, 2026TIME:8:00 a.m. Eastern Time | 6:00 a.m. Mountain TimeWEBCAST:
NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.
SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)
SC 13G - AURORA CANNABIS INC (0001683541) (Subject)
SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)